Combining a PI3 kinase inhibitor with a sodium glucose co-transporter inhibitor or a ketogenic diet was tested in mouse models for 12 cancer types to see if it would shrink tumors.

“So we did a study over the last four years. It took a long time to do this. Lots and lots of mice and lots of experiments to test whether in a mouse model for cancers, a variety of cancers, 12 different types of cancers, if you give a PI3 kinase inhibitor and use either a sodium glucose co-transporter inhibitor or put the patients on a ketogenic diet, which means that they only have about 8% of their total diet as carbohydrate, and even that is slow-release carbohydrate. The rest, 80% is fat and 12% is protein.”